StockNews.AI
ANAB
StockNews.AI
189 days

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

1. AnaptysBio will present data from Phase 2b RENOIR trial on Feb 12, 2025. 2. Rosnilimab targets PD-1+ T cells for rheumatoid arthritis treatment. 3. The data will influence investor perceptions and stock performance. 4. Rosnilimab also in trials for ulcerative colitis and shows broad applications. 5. Other antibodies in the portfolio include ANB033 and ANB101.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive trial data can boost investor confidence, similar to past successful drug results.

How important is it?

The upcoming data presentation is crucial for determining market direction and company valuation.

Why Long Term?

Successful trials contribute to ANAB's valuation over the long term, akin to previous biotech successes.

Related Companies

GSK
February 11, 2025 17:30 ET  | Source: AnaptysBio, Inc. SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT. A live webcast of the call will be available on the Anaptys website at: https://ir.anaptysbio.com/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event. About Anaptys Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.Contact:Nick MontemaranoExecutive Director, Investor Relations858.732.0178investors@anaptysbio.com

Related News